Executive Summary

The Barwon Health Bone Bank is a small human tissue bank located at the Geelong Hospital in Victoria. We exclusively bank femoral heads from live donors having total hip replacement surgery. We provide these as non-irradiated bone for use in orthopaedic procedures, primarily in the Geelong region and occasionally to Bendigo and other areas.

We support the need to provide a safe and reliable tissue service for the Australian public, but we seek to challenge the Therapeutic Goods Committee to review these new regulatory documents with a view to developing a more blood, tissue and cellular therapy specific regulatory vision, rather than a set of manufacturing principles.

We argue, in this submission, that the current model is conceptually and practically flawed and propose a paradigm shift to regulation of blood and tissue banking as a service and not a manufacturing industry. Quality and safety standards should be maintained through “Good Tissue Practice” rather than “Good Manufacturing Practice.” At minimum, we believe a terminology shift to more appropriate language would be beneficial to the regulation and licensing assessment of the sector.

For the benefit of the Australian public, blood, blood components, human tissue and cellular therapy services must be encouraged to expand and develop with emerging technology, in a safe and controlled manner, with a reasonable balance of justified oversight, but without excessive or undue regulatory burden.
Introduction

The Barwon Health – Bone Bank (formerly the Douglas Hocking Research Institute – Bone Bank) is a repository for Human Tissue, donated by public and private patients undergoing Total Hip Replacement (THR) surgery in the Geelong region. Although the Bone Bank is operated by Barwon Health – The Geelong Hospital, we rely on the cooperation and support of the local Orthopaedic Surgeons and the theatre staff of the two local private hospitals. The Orthopaedic surgeons and theatre staff are involved in the screening and consent of donors and collection of donations during Total Hip Replacement surgery. They receive no financial remuneration for their contributions to the bone bank, and there is no cost recovery for the institutions that they work for.

The Barwon Health – Bone Bank collects, stores and supplies fresh frozen (non-irradiated) femoral heads for bone graft in orthopaedic surgery. We aim to provide sufficient stock to meet the needs of our local surgeons and, when sufficient stock is available, we often supply bone to surgeons in Bendigo and other areas upon request. The bank is licensed to ‘manufacture’ this ‘product’ by the Therapeutic Goods Administration (TGA) under the current regulatory regime.

Our small bank is maintained by three core staff members who are employed in a part-time capacity for their bone bank duties. Quality control and medical director roles are fulfilled in a predominantly advisory capacity, which is funded directly by Barwon Health, as the approved ‘cost recovery’ rebate currently allowed through section B of the Prosthesis List is not sufficient to meet these costs.

We are one of only 2 or 3 small banks in the country who struggle to routinely supply this non-irradiated ‘product,’ which our local orthopaedic surgeons prefer over the irradiated alternatives produced by other, mostly larger, bone banks.

The Banks Review\(^1\) discusses the need to reduce the “regulatory creep” that results in unintended and unnecessary, “pervasive effects” on small business. “Regulatory creep” in the human tissue sector gravely jeopardises the future of small, localised banks such as ours. We fear that “regulatory creep” will undoubtedly remove our valued, non irradiated tissue resource from the healthcare system. This is not because of any failure of our bank or the precious tissue we supply, which has been in common medical use for many decades, but because the banks that supply these tissue items will become non-viable under the regulatory and ‘cost recovery’ rebate systems. Obviously, this would be an unintended and unnecessary consequence of the “Therapeutic Goods Act.\(^2\)”

Unfortunately, the current post release ‘cost recovery’ system does not effectively compensate or ensure the long term survival of any tissue bank and “regulatory creep” increases the burden on the tissue sector. Our own recent experience with the requirements for microbiological contamination testing stands as an example of the restrictive consequence of a regulatory burden that potentially threatens the survival of the entire sector.

Our contracted service laboratory ceased providing a TGA licensed microbiological contamination service to us in 2008. The Australian Code of Good Manufacturing Practice for Human Blood and Tissues\(^3\) mandates that this testing be performed in a TGA licensed facility, however, there is no other licensed facility in Victoria that is prepared to meet the regulatory requirements for introducing and validating the culture methods required for our sample types. It
simply is not cost effective, particularly considering the relatively small number of samples to be cultured for us annually. Our microbiological samples could be reliably cultured using similar culture methods, within a couple of hours of collection, at a local pathology service, but the mandate for TGA licensed facilities has required us, at significant additional cost, to transport microbiological specimens from Geelong to Sydney, overnight, to a TGA licensed microbiology laboratory. The samples are ultimately cultured up to 24 hours after collection.

Even under validated transport conditions, the prolonged, interstate transport time clearly cannot enhance our sample or tissue “quality” in any way, yet has served to double our upfront costs. This is an inevitable consequence of the high regulatory burden that has been applied to the sector. There are currently very few microbiology testing laboratories prepared to undertake the onerous process of TGA licensure and it has been our recent experience that many of those that are not directly linked to a blood or tissue service are questioning the cost implications and rational for continuing to provide licensed services.

The additional impacts of this single regulatory requirement illustrate some examples of the very real financial consequences that threaten the existence of our tissue bank service:

- Although the significant additional cost of transport and the higher service fees for the testing were incurred in mid 2008, we were unable to recover these additional costs until our application for a rebate increase on Part B of the Prosthesis List was approved in February 2009 (Please note that that our approved rebate is at a lower rate than was justified in our application).

Consequently, our budget was stretched for more than 6 months, with additional costs incurred for transport and no guarantee that our rebate increase would be approved. This left our public hospital to absorb the additional costs while we waited for the February 2009 List. The alternative would be to close the bank for collections until the additional cost recovery could be guaranteed. Fortunately for orthopaedic patients in Geelong, our hospital’s Chief Executive Officer elected to support the bank financially rather than lose 6 months worth of potential donations.

- If not for the 180 day donor retesting requirement for live donors, which delays the release of tissue until follow-up serology screening is completed, we would never be able to recoup the additional cost of any tissue released before the February 2009 Prosthesis List was published. Although regulatory and ‘cost recovery’ issues are separate, one cannot be considered without consideration to the implications of the other. The impact of regulatory requirements on the financial viability of tissue banking in this country must be considered by the Therapeutic Goods Committee in the review of these draft documents.

There is no opportunity to recover the cost of discarded or non-conforming product, yet significant cost is still incurred.

- The change control for this issue alone took more than 6 months for our part-time staff to complete to a standard that will satisfy the regulatory requirements of the TGA. The biggest issues were firstly, finding an appropriately licensed facility that was willing to take our work, then negotiating and validating a transport method to safely deliver the specimens interstate within defined time and temperature limits.
In the transition period between service contracts, 10% of our donations (and consequently our income) for 2008 was lost, due to an inability to have the specimens cultured. This income loss and 6 months of staff time, diverted from regular duties, will never be recovered or compensated under the current rebate scheme. Thus leaving our local public hospital to absorb the cost.

To meet transport service requirements for overnight delivery, our specimens must be dispatched by 15:00 hours each day. This prevents collection from surgical cases scheduled in the afternoon. As a result, our collection rate in 2009 has been decimated by 40% as compared to 2008. Therefore, on top of the staff time loss for 2008, our ability to generate income to support the service has also been reduced by 40%.

This is just one of the regulatory factors that have contributed a doubling in our Prosthesis List approved rebate from $1,080 to $2,113 on the February 2009 list. The cost of our service, to both public and private healthcare, has increased 5 fold since the introduction of regulation in 1996. Yet we still test, package, store and supply our bone donations in much the same way and there have been no adverse clinical outcomes reported from cases involving tissue from our bank in that time. In fact, our “Audit of the Douglas Hocking Research Institute bone bank: ten years of non-irradiated bone graft” published in 2009, documents that the incidence of deep infection in procedures using our non-irradiated bone, was no greater than the incidence of deep infection for all local joint replacement surgery.

Orthopaedic surgeons, theatre staff, and the healthcare services they work for, receive no compensation for the costs that they incur through their support of the bone bank. Our quality control and medical advisors are likewise unfunded. The true cost of providing human tissue for transplant is not nearly met by the ‘cost recovery’ model, but by the goodwill of healthcare providers who can ill afford the additional expense and individuals who choose to contribute their skills for the greater good of the community.

In this introduction, we have attempted to give the Therapeutic Good Committee an insight into the real implications of the regulatory burden on this, mostly publicly funded, sector. Giving particular focus to the struggle of banks to provide quality tissue items for the community, within the constraints of a ‘not-for-profit,’ ‘cost recovery’ financial system.

We appreciate that the role of the Therapeutic Goods Committee and the Blood and Tissue reference group does not involve the financial considerations of the blood and tissue sector, however, one cannot be considered without the implications to the other. We implore the committee to carefully judge the implications of the additional regulatory requirements that are proposed in these draft documents and to weigh the conundrum of maintaining quality with the reality of continuing to provide a human tissue service.

If the impact of more stringent regulatory standards ultimately reduces our ability to provide tissue services, then it is not the best outcome for the healthcare of Australian citizens?

**General Comments**

The introduction of this new draft of the code represents an opportunity to reconsider some of the manufacturing concepts used in relation to the provision of Blood and Blood components, Human tissues and cellular therapies.
We believe there is a fundamental legislative flaw in defining human tissue items as products. The use of terms such as ‘product’ and ‘manufacture’ consequently lock the human tissue banking sector into a regulatory paradigm developed for manufacturers of inanimate objects and pharmaceuticals. These regulations were never established with the complexities and unique properties of human tissue items or the potential of emerging cellular therapies in mind. Human tissue and cellular therapies do not fit well within the manufacturing framework. We have expressed this view in the current round of government reviews into areas that affect tissue banking and Health Technology Assessment. We see this as a timely opportunity to reassess the definitions and regulation of human tissue items.

The greatest obstacle facing human tissue products in the current regulatory model is that they are not considered in their own context. They are consolidated within an existing system, designed for manufacture of pharmaceuticals and devices, a regulatory system in which they simply do not fit, nor belong. Human tissue items, by their very nature, are as unique and variable as the donor from which they come.

Human tissue ‘products’ are regulated as ‘manufactured’ medical devices, which they clearly are not. Many of the manufacturing principles simply don’t apply to something that is procured from a living being, rather than manufactured from defined and controllable raw materials. The simple fact is that human tissue items are neither ‘manufactured,’ nor are they ‘products’.

Our fear is that the spectre of this manufacturing style of regulation and “regulatory creep” will have negative implications in the future for organ transplant activities and will also stifle the development of cellular therapies from the research lab to clinical application in our “not-for-profit,” “cost recovery” legislated service industry.

If tissue and cellular therapies are to develop and proliferate in this country, then we feel there needs to be a reconsideration of the current regulatory model. The American Association of Tissue Banks in the United States has developed a Code of Good ‘Tissue’ Practice to apply to human tissue banking and presumably cellular therapies. If the principles are based on the provision of a tissue service, then this would seems to be a more enlightened approach to the regulation of human tissue and cellular therapies.

We recommend a brave leap to the use of more appropriate terminology and a refreshed code and standards that reflect the realities and unique nature of the provision of human blood and blood components, human tissues and cellular therapies.

Firstly, it is our view that the provision of human blood and blood components, human tissues and cellular therapies is a ‘service’ industry and not a ‘manufacturing’ industry. We collect altruistic ‘donations’ and ‘process’, not ‘manufacture,’ these as a ‘not-for-profit’ service to provide a therapeutic benefit.

We would like to recommend that the Therapeutic Goods Committee consider a change in the terminology of the code from “products” to “human blood and tissue items” and from “manufacture” to more appropriate term such as “processing” or “preparation”, where relevant.

As any additional requirements in these new draft documents will have significant implications for smaller banks such as us, we urge the Therapeutic Goods Committee to identify the additional requirements and to consider the “real” added quality value versus the potential additional cost of implementation. We hope the committee understands the fragility of the altruistic tissue services
and appreciates that additional regulatory requirements directly increase the cost of providing human blood and tissue items, which will ultimately increase the cost of healthcare.

Specific Comments

<table>
<thead>
<tr>
<th>Clause</th>
<th>Page</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>7. General Requirements</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(6) (b)</td>
<td>7</td>
<td>This clause does not differentiate between transport from another building or institution (e.g. from a separate hospital to the tissue bank) and transport within the same building (e.g. from the theatre suite to the tissue bank within the same building). With regard to transport within one facility, stringent temperature control is not necessarily required for transport within a temperature controlled environment. Although musculoskeletal tissue is most commonly transported at or below 10°C (or wet ice temperatures), this is because of convenient access to wet ice or sample temperature requirements. The quality of musculoskeletal tissue donations is unlikely to be compromised at higher temperatures for a reasonable time period. Therefore, banks should not be restricted by a defined temperature range here. Banks should be allowed to justify and set their own transport temperature requirements.</td>
</tr>
<tr>
<td>(9)</td>
<td>7</td>
<td>There seems to be a grammatical error in the text of this clause that confuses the intent. The initial statement closes with a full stop and does not flow grammatically into points (a), (b) or (c).</td>
</tr>
<tr>
<td>(12)</td>
<td>8</td>
<td>Contradicts itself by stating storage conditions must be validated on data or scientific literature, but then specifies the acceptable storage conditions. Validation of longer or alternative storage conditions must be permitted here.</td>
</tr>
</tbody>
</table>

C:\Documents and Settings\sheppf\Desktop\Submissions\ims\drbloodstandards-sub-ms-bhbb.doc
Thank-you for the opportunity to express our views in this submission. Further information or confidential examples can be obtained by contacting us directly.

Gavin Van Der Meer  
BSc.  
Production Scientist, Barwon Health - Bone Bank  
Laboratory Manager, Barwon Biomedical Research  
Barwon Health  
The Geelong Hospital  
PO Box 281  
Geelong, Victoria 3220  
gavinv@barwonhealth.org.au  
Ph: (03) 5226 7047  
Fax: (03) 5260 3129

Assoc. Prof. Mark Kirkland  
MBBS, PhD, FRCPA  
Medical Director, Barwon Health - Bone Bank  
Laboratory Director, Barwon Biomedical Research  
Barwon Health  
The Geelong Hospital  
PO Box 281  
Geelong, Victoria 3220  
markkl@barwonhealth.org.au  
Ph: (03) 5226 7549  
Fax: (03) 5260 3129

2. Therapeutic Goods Act, 1989  
5. Review of Health Technology Assessment in Australia (the HTA Review)